



Terapet SA and The Politecnico di Milano – Dipartimento di Elettronica, Informazione e Bioingegneria are pleased to announce that they have entered a Research and Development partnership for the coming three years.

Geneva, June 1st, 2021 Terapet SA, a privately held Swiss MedTech company developing innovative solutions for safer, more precise, and time-saving proton therapy for cancer treatment, announced today the start of a new Research and Development partnership with The Politecnico di Milano – [Dipartimento di Elettronica, Informazione e Bioingegneria](#). The R&D collaboration will be led by the head of RadLab (Radiation Detectors and Low-Noise Electronics Laboratory), [Prof. Carlo Fiorini](#) and [Prof. Marco Carminati](#). The collaboration officially starts on 01.06.2021 and will last for the coming 3 years.

“It is our great pleasure to collaborate with one of the world’s best electronics laboratories. The invaluable know-how and the unique competencies of the Politecnico di Milano RadLab will confidently bring us to our next milestones. We are very proud to have built an extremely strong collaboration by gathering the best expertise in the world in a single project with one common goal.” – says CEO, Dr. Christina Vallgren.

“It is a pleasure to start a collaboration with TERAPET and offer our expertise in electronics for new detection solutions in such a stimulating field of application for human health.” - comments Prof. Carlo Fiorini.

“Joining a startup in the challenge of improving range verification in proton therapy is very exciting for the whole team. The scalability of the developed imaging system will be of primary relevance” – notes Prof. Marco Carminati.

In parallel, three other world-class research institutes are also involved in the development of Terapet’s first full-scale prototype: CERN, funded through [the Innosuisse Innovation Project](#), and Karolinska Institute and the first Nordic Proton Therapy facility, Skandion Clinic, funded by Vinnova through the [Eurostars Program](#).

About The Politecnico di Milano – Dipartimento di Elettronica, Informazione e Bioingegneria (DEIB)

The **Politecnico di Milano** is one of the best scientific-technological universities in the world according to the prestigious QS World University Rankings. In 2020, the ranking "by Subject" listed the Politecnico di Milano among the world top 20 in all three specific areas: 20th in Engineering, 10th in Architecture and 5th in Design.

Founded in 1863, it is the oldest of Milan’s universities and Italy’s largest school of Architecture, Design and Engineering with three main centers in Milan and five Campuses. Thanks to a marked internationalization policy, the majority of Master of Science and doctoral programs take place wholly in English. This attracts many international students from more than 100 countries. Teaching is increasingly linked to research, which allows the achievement of high international standards, while creating connections with the business world.

The **Dipartimento di Elettronica, Informazione e Bioingegneria (DEIB)** is one of the largest European ICT departments. With nearly 1000 members, researchers, collaborators, PhD students, technical and administrative staff, the Department is a vital institution capable of promoting education, fundamental and applied research, and technology transfer to companies.

Research is the main focus of DEIB, pursued according to the highest international quality standards. The six department sections cluster consolidated competences in systems and control, computer science and engineering, electronics, telecommunications, bioengineering and electrical engineering. They have a broad network of partnerships with the best international institutions, which makes the Department one of the fundamental players in worldwide scientific and technological innovation. The research activity of the group of Prof. Carlo Fiorini and Prof. Marco Carminati (RadLab) focuses on radiation detectors, both for X-ray and gamma ray detectors, and nuclear electronics. Their know-how and the manpower support will contribute to the development of a dedicated electronics system for Terapet's first full-scale prototype to be installed for clinical validation.

About CERN

[CERN](#), the European Organization for Nuclear Research, is one of the world's largest and most respected centers for scientific research. CERN's main function is to provide the particle accelerators and other infrastructure needed for high-energy physics research – as a result, numerous experiments have been constructed at CERN through international collaborations.

CERN has long been involved in the development of state-of-the-art detector technology - which has found applications beyond high-energy physics in the field of proton therapy. This is a unique opportunity for Terapet to further advance their core technologies with CERN's support, in order to scale up to the full-scale prototype for clinical validation.

Two of the co-founders are former CERN physicists with more than 10 years' experience at CERN.

About Karolinska Institute

The Nobel Prize-awarding [Karolinska Institute](#) in Stockholm, founded in 1810, is Sweden's only university with a core focus on biomedical sciences and ranks as one of the world's leading medical universities, thanks to its high-quality research, which accounts for 40% of all medical research in Sweden.

Karolinska will provide established physics models to quantify and adapt radiotherapy dosages, which will be applied to proton therapy, as well as the clinical expertise needed for the first prototype solution to be adoptable in general clinical practice.

About Skandion Clinic

The [Skandion Clinic](#) in Uppsala, Sweden, is the first clinic in the Nordic region to offer proton radiation treatments and is jointly run by seven Swedish county councils. The clinic opened in 2015 and currently treats ~300 patients every year.

Skandion will act as clinical partner, providing the use of a proton therapy facility and key information on usability from a clinical and practical perspective.

Company Contacts:

Terapet SA
Avenue de Sécheron 15
CH-1202 Geneva, Switzerland
www.terapet.ch
info@terapet.ch

Founders:

Dr. Christina Vallgren
CEO

Dr. Marcus Palm
CTO

Prof. Raymond Miralbell
CSO